Cellectar Biosciences (CLRB) and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement Jun 26, 2025 08:05AM
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement Jun 26, 2025 08:05AM
Cellectar Biosciences (CLRB) Provides Update on CLOVER-2 Phase 1 Trial Jun 11, 2025 08:05AM
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma Jun 11, 2025 08:05AM
Cellectar Biosciences to Present at the 37th Annual Roth Conference Mar 11, 2025 08:05AM
View Older Stories

Mar 5, 2025 08:05AM Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025
Feb 5, 2025 08:05AM Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Jan 12, 2025 06:00PM Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference
Dec 10, 2024 05:01PM Cellectar Biosciences (CLRB) Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
Dec 10, 2024 05:00PM Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
Nov 21, 2024 08:00AM NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)
Nov 14, 2024 08:06AM Cellectar Biosciences (CLRB) and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
Nov 14, 2024 08:05AM Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
Nov 12, 2024 08:05AM Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
Nov 11, 2024 04:05PM Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
Nov 7, 2024 06:40AM Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024
Nov 1, 2024 05:00PM Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q
Aug 26, 2024 06:40AM Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia
Aug 23, 2024 05:00PM Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq
Aug 13, 2024 06:40AM Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update
Aug 8, 2024 05:15PM UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024
Aug 8, 2024 04:05PM Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024
Jul 23, 2024 06:40AM Cellectar Biosciences (CLRB) Reports I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Study
Jul 23, 2024 06:40AM Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months
Jul 22, 2024 06:40AM Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million
Jun 27, 2024 06:40AM Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape
May 29, 2024 06:41AM Cellectar Biosciences (CLRB) and City of Hope Cancer Collaborate to Evaluate Iopofosine I 131 in Mycosis Fungoides
May 29, 2024 06:40AM Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides
May 14, 2024 06:40AM Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update
May 8, 2024 06:40AM Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
May 7, 2024 06:40AM Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024
Mar 27, 2024 06:40AM Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
Mar 20, 2024 06:40AM Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
Mar 14, 2024 08:52AM Cellectar Biosciences to Present at the 36th Annual Roth Conference
Mar 4, 2024 06:41AM Cellectar Biosciences (CLRB) Reports High Rate of Complete Remission in Phase I Study of Iopofosine with External Beam Radiotherapy
Mar 4, 2024 06:40AM Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
Feb 7, 2024 06:40AM Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Jan 30, 2024 06:40AM Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study
Jan 25, 2024 06:41AM Cellectar Biosciences (CLRB) Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1M
Jan 25, 2024 06:40AM Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
Jan 22, 2024 06:40AM Cellectar Biosciences (CLRB) Reports Complete CNS Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient
Jan 22, 2024 06:40AM Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient
Jan 16, 2024 06:42AM Cellectar Biosciences (CLRB) Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors, Releases Promising Preclinical Data
Jan 16, 2024 06:40AM Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data
Jan 12, 2024 06:44AM Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results
Jan 11, 2024 06:40AM Cellectar Biosciences (CLRB) Partners with MiBA to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
Jan 11, 2024 06:40AM Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
Jan 8, 2024 06:31AM Cellectar Biosciences (CLRB) Reports Positive Topline Data Achieving Primary Endpoint in Study of Iopofosine I 131
Jan 8, 2024 06:30AM Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia
Jan 3, 2024 08:30AM Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024
Dec 19, 2023 08:30AM Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation
Dec 12, 2023 08:30AM Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform
Dec 5, 2023 08:30AM Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe
Nov 2, 2023 07:30AM Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024
Oct 25, 2023 08:00AM Cellectar Biosciences Partners with Florida Cancer Specialists & Research Institute to Support the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
View Older Stories